Q-linea AB (3F80) Price & Analysis

Compare

0 Followers

3F80 Stock Chart & Stats

€2.24

Market closed

€2.24

Day’s Range― - ―

52-Week Range€1.87 - €40.99

Previous CloseN/A

VolumeN/A

Average Volume (3M)3.00

Market Cap

€38.34M

Enterprise Value-€102.11M

Total Cash (Recent Filing)€258.11M

Total Debt (Recent Filing)€7.71M

Price to Earnings (P/E)―

Beta86.52

Next Earnings

Apr 30, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.35

Shares Outstanding18,949,081

10 Day Avg. Volume0

30 Day Avg. Volume3

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)0.49

Price to Sales (P/S)14.97

P/FCF Ratio-0.98

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.52

Revenue Forecast (FY)€10.03M

Bulls Say, Bears Say

Bulls Say

Recurring Consumables Revenue ModelQ-linea’s business model centers on instrument sales plus recurring test cartridges and reagents. Durable consumables demand tied to installed instruments can create annuity-like revenue as utilization scales, supporting predictable long-term revenue even if instrument placement is lumpy.

Low Current Debt And Modest Near-term LeverageReported 2025 debt is very low, reducing immediate solvency risk and giving management flexibility. With modest formal leverage the company has more optionality for financing product rollouts or R&D without near-term creditor pressure, important while operating cash flow recovers.

2025 Revenue Rebound Suggests Improving Commercial TractionA ~32% top-line rebound in 2025 indicates renewed adoption of the ASTar platform or consumables. Improving revenue is a structural positive: sustained growth would validate commercial execution, increase installed base and consumable pull-through, and underpin future margin improvement if maintained.

Bears Say

Persistent Negative Gross Profit And Operating LossesNegative gross profit across reporting years signals weak unit economics and that product pricing or cost structure hasn’t reached sustainable levels. Continued large operating losses mean the business cannot self-fund scaling and must rely on external capital until margins turn positive.

Heavy, Consistent Cash Burn And Negative Free Cash FlowDeep, persistent negative operating and free cash flows deplete reserves and raise refinancing risk. Structural cash burn limits the company’s ability to invest in commercialization or R&D without dilutive financing, and makes multi-quarter execution highly sensitive to capital markets access.

Unstable Capital Structure; Equity Turned Negative In 2024A prior period of negative equity shows the balance sheet has been volatile and vulnerable to accumulated losses. Even with equity recovery in 2025, this history increases the likelihood that further external funding or restructuring will be needed if losses persist, pressuring stakeholders.

Q-linea AB News

Q-linea Nomination Committee Proposes Stable Board and New Expertise Ahead of 2026 AGM

The latest update is out from Q-linea AB ( ($SE:QLINEA) ). Q-linea AB’s nomination committee has proposed a...

12d ago

Q-linea Boosts Capital and Global Footprint as ASTar Rollout Accelerates

Q-linea AB ( ($SE:QLINEA) ) has issued an update. Q-linea reported full-year 2025 net sales of SEK 11.1...

2M ago

Q-linea Wins ASTar Contract with Major U.S. Hospital System

Q-linea AB ( ($SE:QLINEA) ) has shared an update. Q-linea AB has signed a contract for the adoption...

2M ago

Q-linea Reshapes US Commercial Leadership to Drive ASTar® Adoption

An announcement from Q-linea AB ( ($SE:QLINEA) ) is now available. Q-linea has announced a reshaping of its...

3M ago

Q-linea Enters South Asian Market With First Distribution Deal in Bangladesh

Q-linea AB ( ($SE:QLINEA) ) has shared an announcement. Q-linea has signed its first distribution agreement in South...

3M ago

Q-linea’s ASTar Chosen to Replace Accelerate Pheno in Italian Laboratories

An announcement from Q-linea AB ( ($SE:QLINEA) ) is now available. Q-linea has been selected to supply its...

3M ago

Q-linea Secures First U.S. Hospital Deployments of ASTar Rapid Testing System

Q-linea AB ( ($SE:QLINEA) ) has shared an update. Q-linea AB has achieved its first clinical implementations of...

3M ago

Q-linea AB Expands Share Capital to Strengthen Market Position

The latest announcement is out from Q-linea AB ( ($SE:QLINEA) ). Q-linea AB has increased its total number...

4M ago

Q-linea Announces Organizational Restructuring and Leadership Changes

An announcement from Q-linea AB ( ($SE:QLINEA) ) is now available. Q-linea AB has announced a reorganization and...

4M ago

Q-linea Submits FDA Application for Expanded ASTar BC G- Panel Claims

Q-linea AB ( ($SE:QLINEA) ) has shared an update. Q-linea AB has submitted a 510(k) application to the...

4M ago

3F80 FAQ

What was Q-linea AB’s price range in the past 12 months?

Q-linea AB lowest stock price was €1.87 and its highest was €40.99 in the past 12 months.

What is Q-linea AB’s market cap?

Q-linea AB’s market cap is €38.34M.

When is Q-linea AB’s upcoming earnings report date?

Q-linea AB’s upcoming earnings report date is Apr 30, 2026 which is in 38 days.

How were Q-linea AB’s earnings last quarter?

Q-linea AB released its earnings results on Feb 04, 2026. The company reported -€0.345 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.345.

Is Q-linea AB overvalued?

According to Wall Street analysts Q-linea AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Q-linea AB pay dividends?

Q-linea AB does not currently pay dividends.

What is Q-linea AB’s EPS estimate?

Q-linea AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Q-linea AB have?

Q-linea AB has 18,949,081 shares outstanding.

What happened to Q-linea AB’s price movement after its last earnings report?

Q-linea AB reported an EPS of -€0.345 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.962%.

Which hedge fund is a major shareholder of Q-linea AB?

Currently, no hedge funds are holding shares in DE:3F80

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Q-linea AB

Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in Sweden. It offers inventive systems for in vitro diagnostics systems for infectious diseases. The company's lead product candidate is ASTar, an antibiotic susceptibility testing system used for positive blood cultures. It develops and delivers solutions for healthcare providers. Q-linea AB (publ) was incorporated in 2008 and is headquartered in Uppsala, Sweden.